Table 2.
Mouse models of signal transduction pathways.
| Gene Mutation | Year | Expression | Mechanism | Phenotype | References |
|---|---|---|---|---|---|
| KrasG12D | 2004 | Inducible | Mx1-Cre | MPD | (82) |
| 2009 | Inducible | Mx1-Cre then transplant | T-ALL/lymphoma, JMML | (83) | |
| +Dnmt3a-/- | 2015 | Inducible | Mx1-Cre | MPD, AML | (84) |
| +PML-RARA | 2006 | Inducible | Mx1-Cre | APL | (85) |
| +RUNX-RUNX1T1 | 2014 | Constitutive | Retrovirus | AML | (86) |
| NrasG12D | 2013 | Inducible | Mx1-Cre | MPD | (87) |
| +Dnmt3a+/- | 2015 | Inducible | Mx1-Cre | MPD/AML | (84) |
| +RUNX1-RUNX1T1 | 2014 | Constitutive | Retrovirus | AML | (88) |
| KIT | 2011 | Constitutive | Retrovirus | MPD | (87) |
| +CBFB-MYH11 | 2012 | Constitutive | Retrovirus | Accelerated AML | (89) |
| +RUNX1-RUNX1T1 | 2011 | Inducible | Retrovirus | AML | (87) |
| FLT3-ITD | 2005 | Constitutive | Retrovirus | MPD | (90) |
| 2005 | Constitutive | Germline – Vav promoter (hematopoietic specific) | MPD | (91) | |
| 2007 | Constitutive | Germline | CMML (AML if combined with KMT2A-PTD, Npm1c, Dnmt3a, RUNX1-RUNX1T1) | (46, 92–95) | |
| 2008 | Inducible | Mx1-Cre | MPD (AML if combined with Npm1c or WT1) | (96–98) | |
| FLT3-TKD | 2005 | Constitutive | Retrovirus | ALL | (90) |
| D835Y | 2014 | Constitutive | Germline | MPD | (99) |
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CMML, chronic myelomonocytic leukemia; JMML, juvenile myelomonocytic leukemia; ITD, internal tandem duplication; MPD, myeloproliferative disease; T-ALL, T-acute lymphoblastic leukemia; TKD, tyrosine kinase domain.